Compass reports tovecimig hits PFS endpoint in BTC Ph2/3; plans BLA submission

Compass Therapeutics, Inc.

Tovecimig + paclitaxel met key secondary PFS endpoint: median 4.7 vs 2.6 months (HR=0.44, p<0.0001).
Primary ORR (previously announced) was 17.1% vs 5.3% (p=0.031); one complete response in tovecimig arm.
OS endpoint not met due to 54% crossover; ITT OS 8.9 vs 9.4 months (HR=1.05, p=0.78).
Crossover patients had median OS 12.8 months vs 6.1 months for non-crossover (HR=0.54, p=0.04).
Company intends to meet with FDA to discuss data in advance of a planned BLA submission for second-line BTC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.